Skip to content

JAZZ

Jazz Pharmaceuticals plc

Stock

$235.67+2.66 (+1.14%)Close Oct 2, 2026

Income statement

LineLast 12 months20252024202320222021202020192018201720162015201420132012201120102009
Revenue$4.6B$4.3B$4.1B$3.8B$3.7B$3.1B$2.4B$2.2B$1.9B$1.6B$1.5B$1.3B$1.2B$872M$586M$272M$174M$128M
R&D$816M$783M$884M$850M$590M$506M$335M$300M$227M$198M$162M$135M$85M$42M$20M$14M$26M$37M
SG&A$1.7B$1.8B$1.4B$1.3B$1.4B$1.5B$854M$737M$684M$544M$503M$449M$406M$304M$224M$109M$69M$59M
Operating income$897M−$430M$717M$579M−$66M$170M$378M$532M$615M$529M$592M$508M$196M$340M$198M$128M$58M$16M
Non-operating income−$169M−$198M−$246M−$281M−$307M−$283M−$103M−$78M−$85M−$88M−$59M−$72M−$44M−$32M−$20M−$2.8M−$25M—
Pretax income$728M−$628M$470M$298M−$373M−$113M$275M$454M$529M$441M$532M$436M$152M$308M$177M$125M$33M—
Taxes−$213M−$272M−$90M−$117M−$149M$217M$36M−$69M$82M−$47M$136M$106M$93M$92M−$111M$0$0—
Net income$941M−$356M$560M$415M−$224M−$330M$239M$523M$447M$488M$397M$330M$58M$216M$289M$125M$33M−$6.8M
Diluted EPS$14.67−$5.84$8.65$6.10−$3.58−$5.52$4.22$9.09$7.30$7.96$6.41$5.23$0.93$3.51$4.79$2.67$0.83−$0.23
Diluted shares—61.0M66.0M72.1M62.5M59.7M56.5M57.6M61.2M61.3M61.9M63.0M62.6M61.6M60.2M46.8M39.4M30.0M
Revenue growth—+4.9%+6.1%+4.8%+18.3%+30.9%+9.3%+14.3%+16.8%+8.8%+12.3%+13.0%+34.4%+48.9%+115.2%+56.7%+35.3%—
Operating margin19.5%−10.1%17.6%15.1%−1.8%5.5%16.0%24.6%32.5%32.7%39.8%38.4%16.7%39.0%33.8%46.9%33.3%12.4%
Net margin20.4%−8.3%13.8%10.8%−6.1%−10.7%10.1%24.2%23.6%30.1%26.7%24.9%5.0%24.8%49.2%45.9%18.9%−5.3%

Revenue to net income